Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient’s immune system — a weakness that in principle could be corrected with a HER2-targeted vaccine — according to a new study.
This full article appears on <a href="http://www.sciencedaily.com/releases/2015/12/151230143816.htm">Science Daily</a>